SLS
SELLAS Life Sciences Group, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Mar 12 SELLAS Life Sciences has enrolled the first patient in a Phase 2 tri…
- R Mar 19 SELLAS Life Sciences reported financial results for 2025, showing re…
- R May 12 SELLAS reported Q1 2026 results with a net loss of $8.4M ($-0.05 EPS…
- E Sep 25 FDA: SELLAS Life Sciences Presents Preclinical Data Demonstrati…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q2 2026: 30 added (0 new), 5 trimmed or exited.
- EstimatesRISING
Current-quarter EPS estimate −$0.055 → −$0.050 over 90 days.
- TrendDOWNTREND
7% below its 50-day average.
- SocialQUIET
Crowd 63° (warm) this week from 8 mentions: 3 bullish, 0 bearish. No setup call. Excludes 2 subscriber-only days.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| STATE STREET CORP | ADD | $191.8M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $31.9M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | DOUBLED | $30.3M |
| JONES FINANCIAL COMPANIES LLLP | ADD | $28.6M |
| NORTHERN TRUST CORP | ADD | $23.9M |
| UBS Group AG | ADD | $18.5M |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | $15.8M |
| WELLINGTON MANAGEMENT GROUP LLP | ADD | $8.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Mar 2026Price is below the lowest target. Median implies +183%.Targets as of Oct 27, 2026.
| Date | Firm | Rating |
|---|---|---|
| Mar 12, 2026 | Maxim Group MAINTAIN | Buy |
| Jul 16, 2025 | Maxim Group MAINTAIN | Buy |
| Nov 22, 2023 | Cantor Fitzgerald REITERATE | Overweight |
| Sep 7, 2023 | Cantor Fitzgerald REITERATE | Overweight |
| Nov 15, 2022 | Alliance Global Partners MAINTAIN | Buy |
| Jun 28, 2022 | Cantor Fitzgerald MAINTAIN | Overweight |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 16, 2026 | Stergiou Angelos M. President and CEO | AWARD | 1,065,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.05 | -$0.05–-$0.05 | +9.1% | $0.00 |
| Next Q | -$0.05 | -$0.05–-$0.05 | +9.1% | $0.00 |
| Current FY | -$0.20 | -$0.20–-$0.20 | +4.8% | $0.00 |
| Next FY | -$0.10 | -$0.20–$0.00 | +20.0% | $53.1M |
Short side
FINRA· Oct 15, 2026SecBot reports
3 filings · 4 press releases · 0 bullish · 0 bearish · 3 neutral- NEUTRAL PRESS RELEASESep 25, 2026
SELLAS Life Sciences presented preclinical data at AACR showing its CDK9 inhibitor SLS009 induced…
Preclinical data supports rationale for SLS009 in pancreatic cancer but does not change near-term valuation. The next catalyst is clinical data from ongoing SLS009 trials in AML or other indications…
- NEUTRAL 8-KJun 2, 2026
SELLAS Life Sciences disclosed it received approximately $28.7 million in warrant exercise…
The warrant exercise proceeds extend the cash runway modestly but do not change the fundamental outlook. Monitor the next quarterly report for updated cash burn rate and pipeline progress.
- NEUTRAL 8-KMay 12, 2026
SELLAS reported Q1 2026 results with a net loss of $8.4M ($-0.05 EPS) vs consensus $-0.06, a 16.7%…
The stock is a binary event play on the REGAL trial readout. With 78 of 80 events reached, the data release could come any day. A positive result would be transformative; a negative result would…
- NEUTRAL DEFA14AApr 23, 2026
SELLAS Life Sciences Group, Inc. (SLS) has filed its definitive proxy statement for the 2026…
This is a standard annual filing with no immediate financial impact. Monitor the company's next 10-Q filing for any changes in guidance or financial performance.
All SLS filing & press-release reports (7)
- PRESS-RELEASE reportSep 25, 2026
- 8-K reportJun 2, 2026
- 8-K reportMay 12, 2026
- DEFA14A reportApr 23, 2026
- PRESS-RELEASE reportMar 19, 2026
- PRESS-RELEASE reportMar 17, 2026
- PRESS-RELEASE reportMar 12, 2026